Aethlon Medical IncAEMD
ASignal's systematic analysis rates AEMD as Neutral.
Reflects the latest available analysis · analyzed Aug 21, 2026
The case on AEMD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current ratio of 5.42x indicates strong short-term liquidity
- Low debt-to-equity ratio of 0.05x suggests minimal leverage risk
- Total cash of $4.93M exceeds total debt of $255,052
- Price above 20-day and 50-day moving averages indicating intermediate-term uptrend
- RSI at 73.93 indicates overbought conditions
- Negative price momentum of -0.1429 suggests recent downward pressure
- Negative forward P/E of -4.74x and negative ROE of -160.91% reflect unprofitability
- Gross, operating, and net margins all at 0.00%
- Enterprise value of -$3.39M indicates negative enterprise value, often a red flag
- No Reddit mentions, suggesting lack of retail investor interest
See the full verdict on AEMD
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AEMD
Most investors never get a second opinion, let alone several. ASignal runs AEMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.